CD4 and colitis: One year later, it was published that Cho et al. administrated PRN 694 in an adoptive T cell transfer model of colitis and detected that this treatment reduced Th1 responses, stopped T cell infiltration into the colon, decreased IL-2 production of transferred CD4+ cells and reduced overall disease progression [48].